Mohamad Tabrizi

Mr. Tabrizi is the acting CEO of Azkarra Therapeutics as well as Managing Director of Pandect Bioventures. Previously, he served as CFO of ShangPharma Innovations. Prior to joining SP Innovation he held executive-level positions in corporate business development at Nektar Therapeutics, and in investor relations and corporate communications roles at Depomed. He also held key positions in healthcare investment banking at Needham & Co., RBC Capital Markets and Merrill Lynch, and served as CFO at Alacritas (Omnicare). In these roles, Mr. Tabrizi led numerous deals spanning the range of royalty monetization, out-licensing and in-licensing, manufacturing and supply, collaborations and partnerships, mergers and acquisitions, and public and private financings including roadshows and venture investments.

Mr. Tabrizi holds a bachelor’s degree in molecular genetics from University of California, Davis; a master’s degree in biological sciences from Stanford University; and an MBA from the S.C. Johnson Graduate School of Management at Cornell University.

‍